Theravance Biopharma

Country

Ownership: -

Employees: 99

Market Cap: -

Website

Introduction: Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Clinical Trials

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: TD-8236
Drug: Placebo

First Posted Date: 2019-11-04

Last Posted Date: 2022-03-18

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 24

Registration Number: NCT04150341

Locations: 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3

Terminated

Conditions: Symptomatic Neurogenic Orthostatic Hypotension

Interventions: Drug: ampreloxetine

First Posted Date: 2019-09-19

Last Posted Date: 2022-11-30

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 110

Registration Number: NCT04095793

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem, Glenview, Illinois, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 52 locations

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TD-5202
Drug: Placebo

First Posted Date: 2019-08-05

Last Posted Date: 2021-01-14

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 56

Registration Number: NCT04044339

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Lincoln, Nebraska, United States

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Phase 2

Terminated

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: TD-1473 Dose C
Drug: TD-1473 Dose A
Drug: TD-1473 Dose B

First Posted Date: 2019-04-18

Last Posted Date: 2022-11-02

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 46

Registration Number: NCT03920254

Locations: 🇺🇦
Theravance Biopharma Investigational Site, Zaporizhzhya, Ukraine
🇺🇦
Theravance Biopharma Investigational Site #2, Lviv, Ukraine

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3

Terminated

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
MSA
Parkinson's Disease (PD)
Pure Autonomic Failure (PAF)

Interventions: Drug: ampreloxetine
Drug: Placebo

First Posted Date: 2019-02-04

Last Posted Date: 2023-01-20

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 203

Registration Number: NCT03829657

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 79 locations

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: TD-1473 Dose C
Drug: TD-1473 Dose B
Drug: TD-1473 Dose A
Drug: Placebo

First Posted Date: 2018-11-29

Last Posted Date: 2022-11-15

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 239

Registration Number: NCT03758443

Locations: 🇺🇦
Theravance Biopharma Investigational Site, Úzhgorod, Ukraine
🇺🇦
Theravance Biopharma Investigational Site #2, Lviv, Ukraine
🇧🇬
Theravance Biopharma Investigational Site (2), Pleven, Bulgaria

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 3

Completed

Conditions: Symptomatic Neurogenic Orthostatic Hypotension

Interventions: Drug: Placebo
Drug: ampreloxetine

First Posted Date: 2018-11-23

Last Posted Date: 2022-09-14

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 195

Registration Number: NCT03750552

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸
NorthShore University Health System, Glenview, Illinois, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 121 locations

Multiple Dose Ethnobridging PK Study in Healthy Subjects

Phase 1

Completed

Conditions: Inflammatory Bowel Diseases
IBD

Interventions: Drug: TD-1473 - Dose A
Drug: TD-1473 - Dose B
Drug: TD-1473 - Dose C
Drug: Placebo

First Posted Date: 2018-11-23

Last Posted Date: 2021-01-14

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 60

Registration Number: NCT03750565

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Cypress, California, United States

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: TD-8236
Drug: Placebo

First Posted Date: 2018-08-29

Last Posted Date: 2021-09-30

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 94

Registration Number: NCT03652038

Locations: 🇬🇧
Theravance Biopharma Investigational Site, Belfast, Northern Ireland, United Kingdom

Efficacy and Safety of TD-1473 in Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: TD-1473
Drug: Placebo

First Posted Date: 2018-08-17

Last Posted Date: 2023-03-13

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 167

Registration Number: NCT03635112

Locations: 🇺🇸
PMG Research of Salisbury, Salisbury, North Carolina, United States
🇬🇧
Theravance Biopharma Investigational Site, Glasgow, Scotland, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy